Case ReviewsMolecular Testing for Fine-Needle Aspiration of Pancreatic Cystic LesionsAdhikari, Laura J. MD; Collins, Brian T. MDAuthor Information From the Cytopathology Section, Department of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO. Reprints: Laura J. Adhikari, MD, Department of Pathology and Immunology, Washington University in St Louis School of Medicine, Campus Box 8118, 660 S Euclid Ave, St Louis, MO 63110. E-mail: email@example.com. The authors have no funding or conflicts to declare. AJSP: Reviews & Reports: July/August 2015 - Volume 20 - Issue 4 - p 143-146 doi: 10.1097/PCR.0000000000000093 Buy Metrics Abstract The incidence of pancreatic cysts in the general population is relatively low, with approximately 2.6% of the adult population and 8% of the elderly population having pancreatic cystic lesions at autopsy. It is now estimated that intraductal papillary mucinous neoplasms account for approximately 3% to 5% of pancreatic neoplasms and 6% of mucinous cystic neoplasms. Serous cystadenomas account for approximately 10% to 15% of cystic lesions of the pancreas, with perhaps an even higher percentage with today’s higher-quality precision imaging studies. In an attempt to standardize a systemic approach to pancreatic cystic lesions, an international multidisciplinary group of physicians met in Sendai, Japan, in 2005, and again revised in 2010, to create guidelines based on treatment outcomes. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.